Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.

被引：1
|
作者：
Hayashi, Kaori
Mitani, Seiichiro
Taniguchi, Hiroya
Hamauchi, Satoshi
Sugiyama, Keiji
Tsushima, Takahiro
Honda, Kazunori
Todaka, Akiko
Masuishi, Toshiki
Yokota, Tomoya
Narita, Yukiya
Machida, Nozomu
Kadowaki, Shigenori
Fukutomi, Akira
Ura, Takashi
Onozawa, Yusuke
Ando, Masashi
Yasui, Hirofumi
Muro, Kei
Yamazaki, Kentaro
机构：
[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Shizuoka Canc Ctr Hosp, Div Med Oncol, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.800
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
800
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Nagashima, Kengo
    Ikezawa, Nobuaki
    Hamaguchi, Tetsuya
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2016, 36 (07) : 3531 - 3536
  • [2] Irinotecan plus cetuximab (Cmab) versus irinotecan plus panitumumab (Pmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) as third-line in daily practice
    Sugimoto, N.
    Hasegawa, A.
    Fujisawa, F.
    Yoshinami, T.
    Yagi, T.
    Imamura, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
    Kennecke, H.
    Chen, L.
    Blanke, C. D.
    Cheung, W. Y.
    Schaff, K.
    Speers, C.
    CURRENT ONCOLOGY, 2013, 20 (06) : 326 - 332
  • [4] Predictive value of primary tumor location: Results from randomized phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)
    Tamura, T.
    Sakai, D.
    Sugimoto, N.
    Tokunaga, S.
    Tsuji, A.
    Ishida, H.
    Otsu, S.
    Moriwaki, T.
    Satake, H.
    Uchino, K.
    Matsumoto, S.
    Baba, E.
    Sato, M.
    Taniguchi, H.
    Kishimoto, J.
    Boku, N.
    Hyodo, I.
    Muro, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [6] Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer
    Hoyle, Martin
    Peters, Jaime
    Crathorne, Louise
    Jones-Hughes, Tracey
    Cooper, Chris
    Napier, Mark
    Hyde, Chris
    VALUE IN HEALTH, 2013, 16 (02) : 288 - 296
  • [7] Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
    ELez, E.
    Kocakova, I.
    Hoehler, T.
    Martens, U. M.
    Bokemeyer, C.
    Van Cutsem, E.
    Melichar, B.
    Smakal, M.
    Csoszi, T.
    Topuzov, E.
    Orlova, R.
    Tjulandin, S.
    Rivera, F.
    Straub, J.
    Bruns, R.
    Quaratino, S.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 132 - 140
  • [8] Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer
    Shitara, Kohei
    Ura, Takashi
    Matsuo, Keitaro
    Takahari, Daisuke
    Yokota, Tomoya
    Yuki, Satoshi
    Yoshida, Motoki
    Utsunomiya, Setsuo
    Sato, Yozo
    Yamaura, Hidekazu
    Kato, Mina
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (18) : 2673 - 2680
  • [9] Panitumumab or cetuximab combined with irinotecan in patients with KRAS wild-type metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
    Ikezawa, Nobuaki
    Iwasa, Satoru
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko T.
    Kato, Ken
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [10] Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis
    Zhang, Chengren
    Liu, Lili
    Lv, Yaochun
    Li, Jingjing
    Cao, Cong
    Lu, Jiyong
    Wang, Shuai
    Du, Binbin
    Yang, Xiongfei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (12) : 1333 - 1348
12345